Experimental antibody aims to repair brain connections in rare dementia

NCT ID NCT07154485

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study tests a new drug called NS101 in 15 people with semantic variant primary progressive aphasia (svPPA), a rare type of frontotemporal dementia that affects language and memory. The drug is an antibody designed to help repair connections between brain cells. The main goal is to check safety, but researchers will also look for signs that it might slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

NS101 (an antibody that may help repair brain cell connections)

What this could lead to

If it works, this could point toward a treatment that slows or improves language and thinking problems in people with this rare form of dementia.

What could go wrong

This is a very early, small study (15 people) focused mainly on safety. It may not show any benefit, and the drug could cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA, FRONTOTEMPORAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

frontotemporal dementia Pick disease semantic dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.